27
Thu, Apr
22 New Articles

AstraZeneca has invested $200m in a new manufacturing facility in China Medical City, Taizhou, Jiangsu province. The new plant will manufacture both intravenous and oral solid medicines.According to the company, the new plant will help meet the rising demand for its products in China besides extending its availability in urban and rural communities that have limited access to established medicines.

More Articles ...

Sign up via our free email subscription service to receive notifications when new information is available.
captcha